argenx SE's total inventories for the quarter that ended in Mar. 2026 was €0 Mil. argenx SE's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €202 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. argenx SE's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €N/A.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
argenx SE's Days Inventory for the
three
months ended in Mar. 2026 was 176.28.
Inventory Turnover measures how fast the company turns over its inventory within a year.
argenx SE's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.52.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
argenx SE's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.18.
argenx SE (FRA:1AE) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
argenx SE's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
argenx SE's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
argenx SE Total Inventories Related Terms
argenx SE Total Inventories Historical Data
* Premium members only.
The historical data trend for argenx SE's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
argenx SE (FRA:1AE) has a Total Inventories of €0 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for argenx SE and its competitors.
Is argenx SE's Total Inventories too high?
argenx SE's current Total Inventories is €0 Mil. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Total Inventories compare to VRTX and REGN?
argenx SE's Total Inventories of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for argenx SE and its competitors. argenx SE's current Total Inventories is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (FRA:1AE) is currently considered Significantly Undervalued. The stock's GF Value™ is €1,163.40, compared to a current price of €753.20 — trading 35.3% below its estimated fair value. The current Total Inventories is €0 Mil. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For argenx SE (FRA:1AE), the current Total Inventories is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (FRA:1AE) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of €753.20 is trading 35.3% below its estimated GF Value™ of €1,163.40.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for FRA:1AE:
Total Inventories: €0 Mil
GF Value™: €1,163.40 vs. price of €753.20 (35.3% below fair value)
No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for FRA:1AE
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1AE has been successfully added to your 
